Gallbladder cancer
Gallbladder cancer is a cancer of the bile-storing sac under the liver, most often found by chance when the gallbladder is removed for stones. Caught early, a second operation to clear the liver bed and nodes can cure it; for advanced disease, chemotherapy now comes with an immunotherapy partner, and HER2-directed antibodies help the subset whose tumours over-express HER2.
Overview
Gallbladder carcinoma is the most common biliary tract cancer worldwide and is grouped with intrahepatic and extrahepatic cholangiocarcinoma in trials and guidelines, so most of its systemic-therapy evidence is borrowed from mixed biliary populations. Chronic inflammation is the driver: gallstones, porcelain gallbladder, chronic Salmonella typhi carriage and anomalous pancreatobiliary junction. Roughly a third to a half of cases are incidental findings at cholecystectomy; for T1b or deeper tumours, radical re-resection (segment IVb/V liver bed, portal lymphadenectomy, and the cystic duct margin) is the curative step, and the BILCAP trial made six months of adjuvant capecitabine the standard after resection of any biliary tract cancer.
Unresectable or metastatic disease is treated with gemcitabine-cisplatin plus a PD-1 or PD-L1 antibody: durvalumab (TOPAZ-1, 2022) or pembrolizumab (KEYNOTE-966, 2023) each added a modest but durable overall-survival benefit over chemotherapy alone, with a long tail of responders. Molecular profiling is now standard at diagnosis because gallbladder tumours carry actionable alterations more often than cholangiocarcinoma: HER2 amplification or over-expression in a meaningful minority (zanidatamab, HERIZON-BTC-01, FDA accelerated approval November 2024), plus occasional BRAF V600E, MSI-high and NTRK fusions. FGFR2 fusions and IDH1 mutations, by contrast, are largely confined to intrahepatic cholangiocarcinoma.
The frontiers are earlier detection in high-incidence regions (ultrasound surveillance of gallbladder polyps and wall thickening, prophylactic cholecystectomy policies), neoadjuvant chemo-immunotherapy for locally advanced tumours, and confirming the HER2 story in randomised trials (HERIZON-BTC-302).
State of the art today
- Immunotherapy added to gemcitabine-cisplatin is the first-line standard after TOPAZ-1 and KEYNOTE-966; the benefit is modest on average but a minority have long, durable responses.
- HER2 is the most useful gallbladder-specific target: zanidatamab won accelerated approval in 2024 and the randomised HERIZON-BTC-302 trial is testing it first line.
- For incidentally found tumours, a timely radical re-resection is the intervention that most changes outcome; the evidence base is retrospective but consistent.
- In high-incidence regions the lever is prevention and early detection: gallstone management, polyp surveillance and cholecystectomy policies, rather than new drugs.
Where it starts and where it drains
Most pancreatic cancers arise in the head next to the bile duct, which is why jaundice is the presenting sign; bile duct cancers are named by where along the tree they sit.
- Pancreatic head (most PDAC)
- Body and tail
- Ampulla
- Islets (pancreatic NET)Neuroendocrine carcinoma of the gallbladder (rare)
- Intrahepatic ducts
- Perihilar (Klatskin)
- Distal bile duct
- GallbladderIncidental gallbladder cancer found at cholecystectomy · Neuroendocrine carcinoma of the gallbladder (rare)
- peripancreatic
- hepatic hilar
- coeliac and superior mesenteric
Same organ: Pancreatic ductal adenocarcinoma, Biliary tract cancer (cholangiocarcinoma), Neuroendocrine tumours, Ampullary cancer (ampulla of Vater)
Rare in most of Europe and North America but common where gallstones are common: northern India, Chile, Bolivia, Pakistan and parts of eastern Europe carry the highest rates (IARC GLOBOCAN).
- AI in radiologyEstablished
- cfDNA fragmentomicsEstablished
- Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)Standard of care
- DNA methylation profilingEstablished
- HCC surveillance in cirrhosis (ultrasound + AFP)Standard of care
- High-risk pancreatic surveillance (CAPS / PRECEDE)Established
- A 28-day national pathway for people with a positive multi-cancer blood test
- A breath test to rule out cancer in people with vague symptoms
- A cancer blood test for older people arriving at A&E with unexplained symptoms
- A legislated, publicly reported 28-day standard from urgent referral to diagnosis
- A live national dashboard of stage at diagnosis as the scorecard for early detection
- A single 'cancer check at 60' appointment bundling all screening tests
Background: CA 19-9, Alpha-fetoprotein (AFP), Barrett's oesophagus, Early detection, Faecal immunochemical test (FIT). Also on OnCo: Symptoms and red flags · Early detection roadmap.
Where the cases are
No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.
Re-resection: liver bed (segments IVb/V) with portal lymphadenectomy, and bile duct excision if the cystic duct margin is positive; port sites are no longer routinely excised.
Adjuvant capecitabine for six months (BILCAP; ASCO guideline 2019); chemoradiation considered for positive margins or node-positive disease.
Gemcitabine-cisplatin plus durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966), with molecular profiling at diagnosis.
FOLFOX (ABC-06); zanidatamab for HER2-positive disease after prior therapy (HERIZON-BTC-01); tumour-agnostic options for MSI-high (pembrolizumab), BRAF V600E (dabrafenib-trametinib) and NTRK fusions (larotrectinib, entrectinib).
Subtypes & biomarkers
top- Adenocarcinoma (most)
- Papillary adenocarcinoma (better outlook)
- Adenosquamous and squamous carcinoma
- Incidental gallbladder cancer found at cholecystectomy
- Neuroendocrine carcinoma of the gallbladder (rare)
- T stage on cholecystectomy pathology (T1a vs T1b or deeper decides re-resection)
- HER2 IHC/ISH (about one in six)
- MSI / mismatch repair
- BRAF V600E
- NTRK fusions
- CA 19-9 (monitoring, not diagnosis)
- Cystic duct margin status
Target prevalence in this cancer
- 1777First description
Maximilian de Stoll describes gallbladder carcinoma at autopsy in Vienna.
- 1954Radical cholecystectomy proposed
Glenn and Hays describe en bloc liver-bed resection with lymphadenectomy.
- 2010Gemcitabine-cisplatin becomes the biliary standard
ABC-02 (NEJM 2010) in a mixed biliary population including gallbladder cancer.
- 2019BILCAP: adjuvant capecitabine
Six months of capecitabine after resection of biliary tract cancer becomes the adjuvant standard.
- 2022TOPAZ-1: durvalumab added to chemotherapy
First immunotherapy survival benefit in biliary tract cancer; FDA approval September 2022.
- 2023KEYNOTE-966: pembrolizumab confirms the class effect
- 2024Zanidatamab for HER2-positive biliary cancer
FDA accelerated approval (November 2024) on HERIZON-BTC-01, in which gallbladder cancer was the largest subgroup.
Open problems, and what is being done about each
Most patients present too late for surgery; ultrasound-based surveillance in high-incidence regions and cholecystectomy policies are being evaluated.
Gallbladder cancer is under-represented and rarely analysed separately in biliary trials; HERIZON-BTC-302 and registry efforts are starting to report it as its own disease.
Which incidentally found T1b tumours truly need re-resection; prospective staging studies are addressing this.
Resistance to HER2 blockade and the small size of other actionable subsets.
and how the field plans to fix it →What is being done about thisResistance to treatmentAvailable now- Comprehensive genomic profilingStandard of care
- AmivantamabApproved
- CamizestrantApproved
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
In trials- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
Ideas and roadmaps- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas: how tumours escape and what closes the route · Lines of therapy.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Expert centres
topCentres linked to this cancer in OnCo
- via Trastuzumab deruxtecan
- Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer CenterBaltimore, USNewsweek oncology #10NCI comprehensivevia Pembrolizumab
- via Trastuzumab deruxtecan
- Cancer Research UKLondon, GBvia BILCAP, ABC-02
- National Cancer Center Hospital EastKashiwa, Chiba, JPvia Trastuzumab deruxtecan, HER2
- via Larotrectinib, Entrectinib
- Alliance for Clinical Trials in OncologyChicago, IL, USvia Pembrolizumab
- via HER2
- German Breast Group (GBG)Neu-Isenburg, DEvia Durvalumab
- GOG FoundationPhiladelphia, PA, USvia Pembrolizumab
- via HER2
- Hospital Universitario 12 de OctubreMadrid, ESvia Durvalumab
- Institut Jules BordetBrussels, BEvia Pembrolizumab
- Instituto Alexander FlemingBuenos Aires, ARvia HER2
- IRCCS Humanitas Research HospitalRozzano (Milan), ITvia Durvalumab
- IRCCS Ospedale San RaffaeleMilan, ITvia HER2
- Istituto di Candiolo IRCCS – FPOCandiolo, ITvia HER2
- via Pembrolizumab
- via HER2
- Peking University Cancer HospitalBeijing, CNvia HER2
- via Trastuzumab deruxtecan
- Rosalind and Morris Goodman Cancer Institute, McGill UniversityMontréal, QC, CAvia HER2
- via HER2
- Weizmann Institute of ScienceRehovot, ILvia HER2
Questions to ask
topQuestions to ask your oncologist about Gallbladder cancer
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Why: Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example T stage on cholecystectomy pathology, HER2 IHC/ISH, MSI / mismatch repair, BRAF V600E, NTRK fusions), and what were the results?Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Why: Recognised subtypes for this cancer include Adenocarcinoma, Papillary adenocarcinoma, Adenosquamous and squamous carcinoma.
- Is germline (inherited) genetic testing recommended for me or my family?Why: Inherited variants can change treatment and matter for relatives.
Incidental cancer at cholecystectomy, T1b or deeper
- For my situation (incidental cancer at cholecystectomy, t1b or deeper), which of the standard options do you recommend and why?Why: Guideline options include: Re-resection: liver bed (segments IVb/V) with portal lymphadenectomy, and bile duct excision if the cystic duct margin is positive; port sites are no longer routinely excised.
After resection
- For my situation (after resection), which of the standard options do you recommend and why?Why: Guideline options include: Adjuvant capecitabine for six months (BILCAP; ASCO guideline 2019); chemoradiation considered for positive margins or node-positive disease.
- How do the results of BILCAP apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Unresectable or metastatic, first line
- For my situation (unresectable or metastatic, first line), which of the standard options do you recommend and why?Why: Guideline options include: Gemcitabine-cisplatin plus durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966), with molecular profiling at diagnosis.
- Am I a candidate for Gemcitabine + cisplatin, Durvalumab, Pembrolizumab, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of TOPAZ-1 and KEYNOTE-966 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Second line and biomarker-directed
- For my situation (second line and biomarker-directed), which of the standard options do you recommend and why?Why: Guideline options include: FOLFOX (ABC-06); zanidatamab for HER2-positive disease after prior therapy (HERIZON-BTC-01); tumour-agnostic options for MSI-high (pembrolizumab), BRAF V600E (dabrafenib-trametinib) and NTRK fusions (larotrectinib, entrectinib).
- Am I a candidate for FOLFOX (5-FU, leucovorin, oxaliplatin), Zanidatamab, Dabrafenib + trametinib or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Zanidatamab, HERIZON-BTC-302, Trastuzumab deruxtecan, Gemcitabine-cisplatin + PD-(L)1 blockade in biliary cancer?Why: Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Why: Supportive care improves quality of life and helps patients complete treatment.
- I read that “Most patients present too late for surgery; ultrasound-based surveillance in high-incidence regions and cholecystectomy policies are being evaluated”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
- I read that “Gallbladder cancer is under-represented and rarely analysed separately in biliary trials; HERIZON-BTC-302 and registry efforts are starting to report it as its own disease”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Direct links plus the targets, companies, and technologies of this cancer's products.
technologies
10targets
7drugs
9companies
9pathways
2terms
5trials
5pairings
1bottlenecks
2Latest papers
topQuery for this cancer: (TITLE:"Gallbladder cancer" OR ABSTRACT:"Gallbladder cancer" OR TITLE:"Gallbladder carcinoma" OR ABSTRACT:"Gallbladder carcinoma" OR TITLE:"Biliary tract cancer of the gallbladder" OR ABSTRACT:"Biliary tract cancer of the gallbladder") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Gallbladder cancer, not a curated reading list.
Pages like this
not linked directly; found by shared links- CancerAmpullary cancer (ampulla of Vater)
Shares CA 19-9, Lymphadenectomy (lymph node dissection), Obstructive jaundice and biliary obstruction, Larotrectinib and the tags nci-coverage, rare, gastrointestinal.
- CancerSmall intestine cancer (small bowel adenocarcinoma)
Shares Lymphadenectomy (lymph node dissection), FOLFOX (5-FU, leucovorin, oxaliplatin), Trastuzumab deruxtecan, The hardest cancers are found late and the tags nci-coverage, rare, gastrointestinal.
- CancerUrethral cancer
Shares Gemcitabine + cisplatin, Rare and paediatric cancers without markets, Cytotoxic chemotherapy, Pembrolizumab and the tags nci-coverage, rare.
- CancerNasal cavity and paranasal sinus cancers (including esthesioneuroblastoma)
Shares Robotic & minimally invasive surgery, Rare and paediatric cancers without markets, Cytotoxic chemotherapy, Pembrolizumab and the tags nci-coverage, rare.
- CancerPenile cancer
Shares Lymphadenectomy (lymph node dissection), Robotic & minimally invasive surgery, Rare and paediatric cancers without markets, Cytotoxic chemotherapy and the tags nci-coverage, rare.
- CancerInflammatory myofibroblastic tumour (IMT)
Shares Entrectinib, Larotrectinib, NTRK, Receptor tyrosine kinase activation and the tags nci-coverage, rare.
- CancerPheochromocytoma and paraganglioma (PPGL)
Shares Receptor tyrosine kinase activation, Merck & Co. (MSD), Rare and paediatric cancers without markets, Cytotoxic chemotherapy and the tags nci-coverage, rare.
- CancerUterine sarcoma
Shares Entrectinib, Larotrectinib, NTRK, Rare and paediatric cancers without markets and the tags nci-coverage, rare.